Fasting glycemia in sleep disordered breathing: lowering the threshold on oxyhemoglobin desaturation
- PMID: 18652097
- PMCID: PMC2491502
Fasting glycemia in sleep disordered breathing: lowering the threshold on oxyhemoglobin desaturation
Abstract
Study objectives: Commonly used definitions of sleep-disordered breathing (SDB) are based on identifying discrete events of breathing abnormalities during sleep that are accompanied by an oxyhemoglobin desaturation (delta SaO2) of at least 4%. However, it is not known whether disordered breathing events with oxyhemoglobin desaturation less than 4% are associated with clinical sequelae such as abnormalities in fasting glycemia.
Design: Cross-sectional study.
Subjects and setting: Participants from the Sleep Heart Health Study (SHHS) with a fasting glucose measurement made within a year of the baseline polysomnogram.
Measurements and results: SDB severity was defined using the apnea-hypopnea index (AHI) and the hypopnea index (HI) by counting events with different levels of oxyhemoglobin desaturation (0.0%-1.9%, 2.0%-2.9%, 3.0%-3.9%, > or = 4.0%). Fasting glucose levels were used to classify individuals into normal (<100 mg/dL), impaired (100-125 mg/dL), and diabetic (> or = 126 mg/dL) groups. Ordinal logistic regression was used to determine the adjusted relative odds of an abnormal glucose value across quartiles of the hypopnea index, independent of factors such as age, body mass index, waist circumference, and usual sleep duration. The prevalence of impaired and diabetic fasting glucose in the analytical sample was 32.9% and 5.8%, respectively. The covariate-adjusted relative odds of impaired or diabetic fasting glucose in the highest versus the lowest AHI quartile was 1.35 (95% CI: 1.04-1.76) for events with a delta SaO2 > or = 4.0%, 1.72 (95% CI: 1.20-2.48) for events with a delta SaO2 between 3.0%-3.9%, 1.41 (95% CI: 1.07-1.86) for events with a delta SaO2 between 2.0%-2.9%, and 1.07 (95% CI: 0.84-1.37) for events with a delta SaO2 between 0.0%-1.9%. The corresponding odds ratios for the HI were 1.47 (95% CI: 1.13-1.92), 2.25 (95% CI: 1.59-3.19), 1.44 (95% CI: 1.09-1.90), and 1.15 (95% CI: 0.90-1.47), respectively.
Conclusions: The results of this study indicate that SDB events accompanied by oxyhemoglobin desaturation of between 2% to 4% are associated with fasting hyperglycemia. These findings suggest that milder degrees of SDB may predispose to adverse metabolic outcomes.
References
-
- Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002;165:1217–39. - PubMed
-
- Punjabi NM, Ahmed MM, Polotsky VY, Beamer BA, O'Donnell CP. Sleep-disordered breathing, glucose intolerance, and insulin resistance. Respir Physiol Neurobiol. 2003;136:167–78. - PubMed
-
- Punjabi NM, Polotsky VY. Disorders of glucose metabolism in sleep apnea. J Appl Physiol. 2005;99:1998–2007. - PubMed
-
- Elmasry A, Janson C, Lindberg E, Gislason T, Tageldin MA, Boman G. The role of habitual snoring and obesity in the development of diabetes: a 10-year follow-up study in a male population. J Intern Med. 2000;248:13–20. - PubMed
-
- Al Delaimy WK, Manson JE, Willett WC, Stampfer MJ, Hu FB. Snoring as a risk factor for type II diabetes mellitus: a prospective study. Am J Epidemiol. 2002;155:387–93. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 HL053916/HL/NHLBI NIH HHS/United States
- R01 HL075078/HL/NHLBI NIH HHS/United States
- U01 HL063463/HL/NHLBI NIH HHS/United States
- HL53938/HL/NHLBI NIH HHS/United States
- HL53934/HL/NHLBI NIH HHS/United States
- U01 HL053938/HL/NHLBI NIH HHS/United States
- HL53931/HL/NHLBI NIH HHS/United States
- U01 HL053941/HL/NHLBI NIH HHS/United States
- AG025553/AG/NIA NIH HHS/United States
- R01 HL086862/HL/NHLBI NIH HHS/United States
- K25 EB003491/EB/NIBIB NIH HHS/United States
- U01 HL053931/HL/NHLBI NIH HHS/United States
- HL53940/HL/NHLBI NIH HHS/United States
- HL63463/HL/NHLBI NIH HHS/United States
- HL086862/HL/NHLBI NIH HHS/United States
- R21 AG025553/AG/NIA NIH HHS/United States
- HL53941/HL/NHLBI NIH HHS/United States
- HL53937/HL/NHLBI NIH HHS/United States
- HL53916/HL/NHLBI NIH HHS/United States
- HL63429/HL/NHLBI NIH HHS/United States
- U01 HL053934/HL/NHLBI NIH HHS/United States
- U01 HL063429/HL/NHLBI NIH HHS/United States
- U01 HL053937/HL/NHLBI NIH HHS/United States
- HL075078/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical